Anzeige
Mehr »
Login
Freitag, 04.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Warum Almonty Industries zum Schlüsselplayer für NATO-Staaten wird
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWF0 | ISIN: US87990A1060 | Ticker-Symbol:
NASDAQ
03.04.25
21:59 Uhr
0,523 US-Dollar
-0,043
-7,58 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TENAYA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
TENAYA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur TENAYA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
TENAYA THERAPEUTICS Aktie jetzt für 0€ handeln
MoTenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting91TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase Over Time All Cohort 1 Patients with...
► Artikel lesen
28.03.Tenaya Therapeutics, Inc. - 8-K, Current Report4
25.03.Tenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in March8
24.03.Tenaya reports promising gene therapy for heart condition5
24.03.Tenaya Therapeutics, Inc.: Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models246SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially...
► Artikel lesen
21.03.Tenaya Therapeutics announces $300M mixed shelf offering; shares down6
19.03.Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session101SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially...
► Artikel lesen
13.03.Canaccord cuts Tenaya Therapeutics price target to $68
11.03.H.C. Wainwright cuts Tenaya Therapeutics price target to $510
10.03.Tenaya Therapeutics GAAP EPS of -$0.28 beats by $0.045
10.03.Tenaya Therapeutics, Inc. - 10-K, Annual Report3
10.03.Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update110Dosing Initiated in Cohort 2 of the MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Cohort 1 Data Accepted for Late-Breaker Presentation...
► Artikel lesen
04.03.Tenaya Therapeutics, Inc. - 8-K, Current Report19
04.03.Tenaya Therapeutics stock dives after pricing offering to raise $52.5 million32
04.03.Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Pricing of Public Offering197SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially...
► Artikel lesen
03.03.Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Proposed Public Offering6
07.02.Tenaya Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans17
07.02.Tenaya Therapeutics, Inc. - 8-K, Current Report9
04.02.H.C. Wainwright maintains buy rating on Tenaya Therapeutics stock31
28.01.Tenaya Therapeutics, Inc. - 8-K, Current Report6
Seite:  Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3